Verastem Oncology宣布，其口服、潜在同类最佳在研KRAS G12D（开/关）抑制剂VS-7375，已获得美国食品药品监督管理局（FDA）的快速通道认定。该药物旨在用于治疗携带KRAS G12D突变的局部晚期或转移性非小细胞肺癌（NSCLC）患者。
快速通道认定旨在加速针对严重疾病且能填补未满足医疗需求的药物的开发和审评进程。这一认定意味着VS-7375有潜力解决KRAS G12D突变NSCLC这一关键临床需求领域。对于Verastem而言，这是其管线推进的一个重要监管里程碑。
Verastem Oncology宣布，其口服、潜在同类最佳在研KRAS G12D（开/关）抑制剂VS-7375，已获得美国食品药品监督管理局（FDA）的快速通道认定。该药物旨在用于治疗携带KRAS G12D突变的局部晚期或转移性非小细胞肺癌（NSCLC）患者。
快速通道认定旨在加速针对严重疾病且能填补未满足医疗需求的药物的开发和审评进程。这一认定意味着VS-7375有潜力解决KRAS G12D突变NSCLC这一关键临床需求领域。对于Verastem而言，这是其管线推进的一个重要监管里程碑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.